||Small molecule PI3K inhibitor
||Solid tumours, various cancers
|Mode of Action
||The phosphatidylinositol-3-kinase/protein-kinase-B signalling pathway – PI3K in short – sends a “growth” signal to the nucleus of a tumour cell. It has been shown that abnormal mutations of the PI3K signalling pathway are present in most types of cancer. Identifying an inhibitor for the PI3K signalling pathway is thus of therapeutic interest.
||In February 2012 WILEX announced that it had been granted funding of up to EUR 2.6 million from the German Federal Ministry of Education and Research (BMBF) for the pre-clinical and clinical development of WX-037. Preclinical work on WX-037 has been completed and clinical development has started in August 2013.
||The PI3K inhibitor project was acquired from UCB at the beginning of 2009.
Seite gelesen: 3330 | Heute: 5